AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02283151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diet nutrition bar
Description: The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake \< 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (\<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
Study NCT02283151 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: energy-restricted diet
Description: The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
Study NCT01322308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 30 mg tablet QD (taken once daily)
Study NCT01322308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet taken once a day
Study NCT02370446 — intervention group
Intervention type: OTHER
Intervention: personalized medication log
Study NCT02370446 — intervention group
Intervention type: OTHER
Intervention: standard of care
Study NCT02370446 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Study NCT02370446 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Interview
Study NCT02749123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 5% patch
Description: 10cmx 14 cm transdermal patch sealed in its own pouch
Study NCT02749123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine 3.6%, menthol 1.25%
Description: 10cmx 14 cm transdermal patch sealed in its own pouch
Study NCT02749123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 3.6%, menthol 1.25%
Description: 10cmx 14 cm transdermal patch sealed in its own pouch
Study NCT02749123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
Study NCT01240265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 150,000 IU orally given once
Study NCT01240265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 5000 IU given orally daily for 28 days
Study NCT03233269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
Study NCT02197455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib Administration
Description: 5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
Study NCT03733431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gammacore device
Description: Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
Study NCT03733431 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gammacore sham device
Description: Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
Study NCT04254042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril Arginine
Description: 10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study NCT04254042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer
Description: 30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study NCT03355443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroflexion
Description: Retroflexion technique in colonoscopy means turning the colonoscope tip 180 degree in order to look backward in the colon and rectum.
Study NCT03355443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-examination
Description: Re-examination in colonoscopy means examining the cecum and ascending colon twice in the routine fashion.
Study NCT03490162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM1157
Description: DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
Study NCT03490162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00911443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg
Description: Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
Study NCT00911443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg
Description: Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
Study NCT00911443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg
Description: Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
Study NCT00911443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dacarbazine + Thymosin-alpha-1 3.2 mg
Description: Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
Study NCT00911443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine + Interferon alpha
Description: Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
Study NCT00002779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00002779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Study NCT02592187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReMemory-MCI training
Study NCT02592187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Study NCT02531243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALMS
Description: Family Therapy; Multi-user Biofeedback Videogames
Study NCT03729362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cipaglucosidase Alfa
Description: Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).
Study NCT03729362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
Study NCT03729362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alglucosidase Alfa
Description: Participants received an IV infusion dose over a 4-hour duration Q2W.
Study NCT03729362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
Study NCT00967928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
Study NCT00967928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
Study NCT00967928 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Whole Pelvis Radiation Therapy
Description: Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
Study NCT04491097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Panavia V5 resin cement
Description: Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia V5 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
Study NCT04491097 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Panavia F2.0 resin cement
Description: Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia F2.0 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
Study NCT06738693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Fixation
Description: External fixation involves the stabilization of unstable intra-articular distal radius fractures using an external fixator. The procedure is performed under anesthesia, with fixator pins placed percutaneously into the proximal and distal fragments of the radius. Postoperative care includes regular cleaning of pin tracts, early mobilization exercises for adjacent joints, and fixator removal upon radiological confirmation of fracture healing, typically between 6 to 8 weeks post-surgery.
Study NCT06738693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF) with Volar Locking Plate
Description: ORIF using a volar locking plate is performed to anatomically reduce and stabilize unstable intra-articular distal radius fractures. The procedure is conducted under anesthesia, involving an open approach through the volar aspect of the wrist. The volar locking plate is secured with screws to provide rigid fixation, enabling early mobilization. Postoperative follow-up includes evaluation of functional outcomes, union rates, and potential complications.
Study NCT03315806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: 140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
Study NCT03315806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140 mL of beetroot juice isent of nitrate
Study NCT01046097 — intervention group
Intervention type: BIOLOGICAL
Intervention: Synflorix™
Description: Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
Study NCT02415127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon γ-1b
Description: The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
Study NCT02415127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
Study NCT03669250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN058
Description: CVN058 will be given at two doses, a low does and a high dose
Study NCT03669250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: inactive placebo
Study NCT00624286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT00624286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT05759715 — intervention group
Intervention type: OTHER
Intervention: Iris Color Measurement , LF/HF Measurement
Description: Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
Study NCT02267707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
Study NCT02267707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
Study NCT04756921 — intervention group
Intervention type: DRUG
Intervention: Pyrotinib
Description: Pyrotinib 400mg po qd
Study NCT01003938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study NCT01003938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT03961828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
Description: The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
Study NCT01572051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Course
Description: 2 Educational courses
Study NCT01572051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Phone Calls
Study NCT01572051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material
Study NCT01545193 — intervention group
Intervention type: OTHER
Intervention: Age and incidence of residual neuromuscular blockade
Description: An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
Study NCT01780051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide/Metformin combination, Repaglinide, Metformin
Description: Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2.
Study NCT01780051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide/Metformin combination, Repaglinide, Metformin
Description: Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2.
Study NCT02550535 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous WT1 TCR transduced T cells
Description: Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
Study NCT04904094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casting of the lower limb and homebased stretching exercise program.
Description: Lower leg casting in combination with removable upper leg casts for approximately 2 weeks and stretching exercises during casting and 4 weeks after casting.
Study NCT00506376 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview that will take about 20 minutes to complete.
Study NCT02827097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denogan and rectus sheath block
Description: administration of denogan and rectus sheath block with 0.375% ropivacaine
Study NCT02827097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: denogan
Description: administration of denogan
Study NCT03256396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP setting based on esophageal pressure measured
Description: PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
Study NCT02974907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-259
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
Study NCT02974907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Study NCT03078608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation program (administered via mobile app)
Description: Mobile app-based/online mindfulness meditation program
Study NCT03078608 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness meditation program (administered via mobile app)
Description: Mobile app-based/online mindfulness meditation program
Study NCT03078608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation (via mobile app)
Description: Mobile app-based/online progressive muscle relaxation program
Study NCT02555137 — intervention group
Intervention type: OTHER
Intervention: 'prediction score' and 'rule-out criteria'
Description: The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
Study NCT00774540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Ketorolac intraarticular
Description: Ketorolac intraarticular 5 mg
Study NCT00774540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT04471116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OMNi-BiOTiC® FLORA plus+
Description: OMNi-BiOTiC® FLORA plus + is a dietary supplement for the treatment of a disturbed vaginal flora (dysbiosis). The product combines probiotic bacterial strains with a special fiber mixture. The product contains the following strains: Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116
Study NCT00503919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-spectral Digital Colposcopy (MDC)
Description: Use of a digital camera and a special light to take pictures of the cervix and vagina.
Study NCT01677338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C-uracil
Description: PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
Study NCT06738511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling
Description: Molecular signature using plasma sample
Study NCT06738511 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: stool sampling
Description: Stool sampling (by the participant)
Study NCT01494857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
Study NCT06738511 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: colonoscopy
Description: Colonoscopy will be performed in the course of a screening programme
Study NCT02256878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX
Study NCT02256878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Study NCT03235492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartAlbu
Description: Plan:~1. Consent an individual~2. Measure and record temperature, blood pressure, heart rate, height and weight~3. Obtain two samples of saliva for the SmartAlbu portable salivary sensor~4. Take a venous blood sample for HbA1c and~5. Glycated albumin~6. Obtain blood sample from a finger stick for point of care HbA1c device
Study NCT02232321 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PsA MDA